Neogenomics Inc Dossier
Qualitative Analysis
Business overview
NeoGenomics, Inc. (NASDAQ: NEO) is a premier cancer diagnostics and information services company specializing in oncology genetics testing. Operating primarily through its clinical laboratory network, the company offers a comprehensive oncology-focused testing menu across the cancer continuum. Its services include cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry (IHC), anatomic pathology, and next-generation sequencing (NGS). NeoGenomics serves pathologists, oncologists, hospital systems, academic centers, and pharmaceutical companies, positioning itself as a critical partner in precision medicine and community oncology settings.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Commercializing and scaling the RaDaR ST assay to target the estimated $20 billion addressable molecular residual disease monitoring market.
Expected impact: Positioning NeoGenomics as a leader in the high-growth recurrence monitoring space, driving long-term revenue growth.
Expanding the PanTracer family of therapy selection solutions, including the launch of PanTracer Pro and PanTracer LBx, to capture market share in advanced-stage solid tumors.
Expected impact: Sustaining above-market NGS growth (which grew 26% YoY in Q1 2026) and shifting the portfolio mix toward higher-margin tests.
Implementing a desiloing sales model and expanding the sales force to increase market penetration among community oncologists.
Expected impact: Doubling close rates and deal sizes by targeting high-potential physicians and capturing a larger share of wallet in community oncology.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Strengthens NeoGenomics' commercial presence in the Northeast U.S. and brings critical New York State (NYS) laboratory approvals, accelerating growth in molecular and hematology-oncology testing.
Financial impact: Contributed an estimated $12 million to $14 million in annualized revenue and expected to be accretive to Adjusted EBITDA starting in 2026 through cost synergies.
Strategic Partnerships
Integrates Adaptive's FDA-cleared clonoSEQ next-generation sequencing test for lymphoid cancers with NeoGenomics' COMPASS and CHART personalized assessment services.
Terms: Multi-year exclusive agreement; specific financial terms were not publicly disclosed.